Prostate News Archive
17-Feb-2008
EPCA-2 testing more accurate way to identify cancer in the prostate (News-Medical-Net)
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer - a disease that kills tens of thousands of men every year. GTX Shares Fall on Study Concern (AP via Yahoo! Finance)
Shares of biotechnology company GTX Inc. stumbled Monday on concerns on the risks involved with a late-stage study of the company's prostate cancer drug Acapodene. Prostate Cancer Conference at Mayo Clinic (KAAL Austin)
(KAAL) -- It's a type of cancer that some call the "couple disease". The Mayo Clinic in Rochester held a conference on prostate cancer, allowing men to gather information they and their loved ones may need in order to deal with the disease and life after. The Risk Of Renal Impairment In Hormone-Refractory Prostate Cancer Patients With Bone Metastases Treated With ... (Medical News Today)
UroToday.com- Nearly one-quarter of prostate cancer (CaP) patients treated with zoledronic acid (ZA) suffer renal impairment according to a report by Dr. Oh and colleagues in the online version of Cancer.ZA is an intravenous bisphosphonate given to decrease skeletal related events in CaP patients with bone metastases. [click link for full article]
Back to Prostate News Archive
